The main culprits
| Class | Examples | Better-tolerated alternatives to discuss |
|---|---|---|
| Thiazide diuretics | Hydrochlorothiazide, chlortalidone | ACE inhibitors, ARBs or calcium channel blockers, if clinically appropriate |
| Older beta-blockers | Propranolol, atenolol, metoprolol | Nebivolol has a more favourable sexual profile and is sometimes substituted |
| SSRIs and SNRIs | Paroxetine, sertraline, venlafaxine | Bupropion, mirtazapine or vortioxetine |
| 5-alpha-reductase inhibitors | Finasteride, dutasteride | Alpha-blockers such as tamsulosin, or tadalafil for BPH |
| Antipsychotics | Risperidone, haloperidol | Agents with less prolactin elevation, such as aripiprazole |
| Anti-androgens / ADT | Leuprolide, bicalutamide | Rarely substitutable — the sexual effect is the intended mechanism |
| Opioids | Oxycodone, morphine, methadone | Dose reduction, non-opioid analgesia, or treating the resulting hypogonadism |
| Older antihistamines | Diphenhydramine, chlorphenamine | Non-sedating alternatives such as loratadine or cetirizine |
| H2 blockers | Cimetidine | Famotidine or a proton pump inhibitor |
| Spironolactone | — | Alternative diuretic where the indication allows |
Blood pressure medication in particular
This is the most consequential group, because hypertension itself causes erectile dysfunction — so the drug and the disease are easily confused. There is one clear practical point: the class matters.
- Thiazides and older beta-blockers are the most frequently implicated.
- ACE inhibitors, ARBs and calcium channel blockers are generally neutral, and some data suggest ARBs may be slightly favourable.
- Nebivolol, a beta-blocker with nitric oxide-mediated vasodilating properties, appears better tolerated sexually than older beta-blockers.
Finasteride, dutasteride and the persistence question
5-alpha-reductase inhibitors are used for benign prostatic hyperplasia and, at lower doses, for male pattern hair loss. They block the conversion of testosterone to dihydrotestosterone. Sexual side effects — reduced libido, erectile difficulty, reduced ejaculate volume — are documented in the product labelling and in trials, affecting a minority of users.
The contested question is whether symptoms can persist after stopping — sometimes called post-finasteride syndrome. Regulators in several countries have required warnings about persistent sexual dysfunction; the scientific debate about causation and frequency continues, and the evidence remains genuinely unsettled.
How to raise it with your prescriber
- Establish the timeline. When did the ED start, and what medication changed in the weeks before? Write it down before the appointment.
- Bring a full list, including over-the-counter medicines and supplements.
- Ask directly: 'Is any of this likely to be contributing, and is there an alternative in the same class?'
- Ask about a trial switch with a defined review date, rather than an open-ended change.
- Do not stop anything in the meantime. Continue as prescribed until you have agreed a plan.
Frequently asked questions
How do I know if my medication is causing my ED?
Can I just stop the medication to find out?
Do statins cause ED?
Will the problem resolve if I switch?
What this is based on
We link to primary sources — clinical guidelines, regulator publications and peer-reviewed research — wherever possible. Links open on third-party sites we do not control.
- [01]MedlinePlus (National Library of Medicine). Drugs, Herbs and Supplements.
- [02]U.S. Food and Drug Administration. Drugs@FDA — approved drug products and prescribing information.
- [03]American Urological Association. Erectile Dysfunction: AUA Guideline (2018).
- [04]Mayo Clinic. Erectile dysfunction — symptoms and causes.